Chromogranin A as Blood Marker in Cancer Patients

CompletedOBSERVATIONAL
Enrollment

175

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

December 14, 2021

Study Completion Date

December 14, 2021

Conditions
Gastric NeoplasmsPancreatic NeoplasmsSmall Intestinal NeoplasmsColorectal Neoplasms
Interventions
DIAGNOSTIC_TEST

BRAHMS CgA II KRYPTOR

"The BRAHMS CgA II KRYPTOR kit is an automated immunofluorescent assay for the quantitative determination of the concentration of CgA in human serum.~The assay is to be used as an aid in monitoring disease progression during the course of disease and treatment in patients with GEP-NETs (grade 1 and grade 2).~Serial testing for patient BRAHMS CgA II KRYPTOR assay values should be used in conjunction with other clinical methods for monitoring GEP-NETs (grade 1 and grade 2)."

Trial Locations (4)

55905

Mayo Clinic, Rochester

77030

The University of Texas MD Anderson Cancer Center, Houston

94305

Stanford University Medical Center, Palo Alto

Unknown

Charité - Universitätsmedizin Berlin, Berlin

All Listed Sponsors
lead

Brahms AG

INDUSTRY

NCT03817866 - Chromogranin A as Blood Marker in Cancer Patients | Biotech Hunter | Biotech Hunter